Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans
To the Editor: Ojji et al. (June 20 issue) 1 report that amlodipine plus hydrochlorothiazide effectively lowered blood pressure at 6 months in black patients in sub-Saharan Africa. Many primary care providers are unaware of the association between hydrochlorothiazide use and skin cancer. 2 The Medic...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2019-10, Vol.381 (14), p.1389-1392 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1392 |
|---|---|
| container_issue | 14 |
| container_start_page | 1389 |
| container_title | The New England journal of medicine |
| container_volume | 381 |
| creator | Dominguez-Rodriguez, Alberto Baez-Ferrer, Nestor Abreu-Gonzalez, Pedro KagboKue, Suaka Chineke, Iloabueke Bakinde, Nicholas Schwartz, Jeremy I Ssinabulya, Isaac Quashie, Nekehia T Howitt, Christina Hambleton, Ian R Ojji, Dike B Poulter, Neil |
| description | To the Editor:
Ojji et al. (June 20 issue)
1
report that amlodipine plus hydrochlorothiazide effectively lowered blood pressure at 6 months in black patients in sub-Saharan Africa. Many primary care providers are unaware of the association between hydrochlorothiazide use and skin cancer.
2
The Medicines and Healthcare Products Regulatory Agency has reported a dose-dependent risk of lip and skin cancers among patients taking hydrochlorothiazide.
2
Regarding melanoma,
3
413 cases were identified among high users of hydrochlorothiazide (patients who had taken a cumulative dose of ≥50,000 mg of hydrochlorothiazide), yielding an adjusted odds ratio of 1.22 (95% confidence interval [CI], 1.09 to 1.36), . . . |
| doi_str_mv | 10.1056/NEJMc1909844 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2300597847</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2300595809</sourcerecordid><originalsourceid>FETCH-LOGICAL-c652t-7eada79d8c45719bde6913ec00a646bbef710e45eadffd8c32a4cb6e912881033</originalsourceid><addsrcrecordid>eNqN0U1P3DAQBmALgWCh3DgjS_TAgdBxbMf2EbYLFG0_Dss5cpxJm20SLzYR6r_H7QJCFYedy0ijR-9hXkKOGJwzkMWnb7Pbr44ZMFqILTJhkvNMCCi2yQQg15lQhu-R_RiXkIYJs0v2OJNKaS0n5Hbq-5UNbfQD9Q39PNqOLn5hsKsWI218oHP_iKEdftLLzvua_ggY4xiQtkO6WPebXjShdXaIH8hOY7uIh8_7gNxdzRbTm2z-_frL9GKeuULmD5lCW1tlau2EVMxUNRaGcXQAthBFVWGjGKCQiTVNUjy3wlUFGpZrzYDzA3K6zl0Ffz9ifCj7NjrsOjugH2OZcwBplBZqQ1oonW9Kc9iUSg0m0ZP_6NKPYUjv-adynl4CSZ2tlQs-xoBNuQptb8OfkkH5t-TybcmJHz-HjlWP9St-aTWBj2vQ97EccNm_n_ME0Y6pqA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2300236520</pqid></control><display><type>article</type><title>Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Dominguez-Rodriguez, Alberto ; Baez-Ferrer, Nestor ; Abreu-Gonzalez, Pedro ; KagboKue, Suaka ; Chineke, Iloabueke ; Bakinde, Nicholas ; Schwartz, Jeremy I ; Ssinabulya, Isaac ; Quashie, Nekehia T ; Howitt, Christina ; Hambleton, Ian R ; Ojji, Dike B ; Poulter, Neil</creator><creatorcontrib>Dominguez-Rodriguez, Alberto ; Baez-Ferrer, Nestor ; Abreu-Gonzalez, Pedro ; KagboKue, Suaka ; Chineke, Iloabueke ; Bakinde, Nicholas ; Schwartz, Jeremy I ; Ssinabulya, Isaac ; Quashie, Nekehia T ; Howitt, Christina ; Hambleton, Ian R ; Ojji, Dike B ; Poulter, Neil</creatorcontrib><description>To the Editor:
Ojji et al. (June 20 issue)
1
report that amlodipine plus hydrochlorothiazide effectively lowered blood pressure at 6 months in black patients in sub-Saharan Africa. Many primary care providers are unaware of the association between hydrochlorothiazide use and skin cancer.
2
The Medicines and Healthcare Products Regulatory Agency has reported a dose-dependent risk of lip and skin cancers among patients taking hydrochlorothiazide.
2
Regarding melanoma,
3
413 cases were identified among high users of hydrochlorothiazide (patients who had taken a cumulative dose of ≥50,000 mg of hydrochlorothiazide), yielding an adjusted odds ratio of 1.22 (95% confidence interval [CI], 1.09 to 1.36), . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1909844</identifier><identifier>PMID: 31577885</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Black People ; Blood Pressure ; Health risk assessment ; Humans ; Hydrochlorothiazide ; Hypotension ; Melanoma ; Skin cancer</subject><ispartof>The New England journal of medicine, 2019-10, Vol.381 (14), p.1389-1392</ispartof><rights>Copyright © 2019 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c652t-7eada79d8c45719bde6913ec00a646bbef710e45eadffd8c32a4cb6e912881033</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1909844$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2300236520?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,2759,2760,26103,27924,27925,52382,54064,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31577885$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dominguez-Rodriguez, Alberto</creatorcontrib><creatorcontrib>Baez-Ferrer, Nestor</creatorcontrib><creatorcontrib>Abreu-Gonzalez, Pedro</creatorcontrib><creatorcontrib>KagboKue, Suaka</creatorcontrib><creatorcontrib>Chineke, Iloabueke</creatorcontrib><creatorcontrib>Bakinde, Nicholas</creatorcontrib><creatorcontrib>Schwartz, Jeremy I</creatorcontrib><creatorcontrib>Ssinabulya, Isaac</creatorcontrib><creatorcontrib>Quashie, Nekehia T</creatorcontrib><creatorcontrib>Howitt, Christina</creatorcontrib><creatorcontrib>Hambleton, Ian R</creatorcontrib><creatorcontrib>Ojji, Dike B</creatorcontrib><creatorcontrib>Poulter, Neil</creatorcontrib><title>Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>To the Editor:
Ojji et al. (June 20 issue)
1
report that amlodipine plus hydrochlorothiazide effectively lowered blood pressure at 6 months in black patients in sub-Saharan Africa. Many primary care providers are unaware of the association between hydrochlorothiazide use and skin cancer.
2
The Medicines and Healthcare Products Regulatory Agency has reported a dose-dependent risk of lip and skin cancers among patients taking hydrochlorothiazide.
2
Regarding melanoma,
3
413 cases were identified among high users of hydrochlorothiazide (patients who had taken a cumulative dose of ≥50,000 mg of hydrochlorothiazide), yielding an adjusted odds ratio of 1.22 (95% confidence interval [CI], 1.09 to 1.36), . . .</description><subject>Black People</subject><subject>Blood Pressure</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Hydrochlorothiazide</subject><subject>Hypotension</subject><subject>Melanoma</subject><subject>Skin cancer</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqN0U1P3DAQBmALgWCh3DgjS_TAgdBxbMf2EbYLFG0_Dss5cpxJm20SLzYR6r_H7QJCFYedy0ijR-9hXkKOGJwzkMWnb7Pbr44ZMFqILTJhkvNMCCi2yQQg15lQhu-R_RiXkIYJs0v2OJNKaS0n5Hbq-5UNbfQD9Q39PNqOLn5hsKsWI218oHP_iKEdftLLzvua_ggY4xiQtkO6WPebXjShdXaIH8hOY7uIh8_7gNxdzRbTm2z-_frL9GKeuULmD5lCW1tlau2EVMxUNRaGcXQAthBFVWGjGKCQiTVNUjy3wlUFGpZrzYDzA3K6zl0Ffz9ifCj7NjrsOjugH2OZcwBplBZqQ1oonW9Kc9iUSg0m0ZP_6NKPYUjv-adynl4CSZ2tlQs-xoBNuQptb8OfkkH5t-TybcmJHz-HjlWP9St-aTWBj2vQ97EccNm_n_ME0Y6pqA</recordid><startdate>20191003</startdate><enddate>20191003</enddate><creator>Dominguez-Rodriguez, Alberto</creator><creator>Baez-Ferrer, Nestor</creator><creator>Abreu-Gonzalez, Pedro</creator><creator>KagboKue, Suaka</creator><creator>Chineke, Iloabueke</creator><creator>Bakinde, Nicholas</creator><creator>Schwartz, Jeremy I</creator><creator>Ssinabulya, Isaac</creator><creator>Quashie, Nekehia T</creator><creator>Howitt, Christina</creator><creator>Hambleton, Ian R</creator><creator>Ojji, Dike B</creator><creator>Poulter, Neil</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20191003</creationdate><title>Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans</title><author>Dominguez-Rodriguez, Alberto ; Baez-Ferrer, Nestor ; Abreu-Gonzalez, Pedro ; KagboKue, Suaka ; Chineke, Iloabueke ; Bakinde, Nicholas ; Schwartz, Jeremy I ; Ssinabulya, Isaac ; Quashie, Nekehia T ; Howitt, Christina ; Hambleton, Ian R ; Ojji, Dike B ; Poulter, Neil</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c652t-7eada79d8c45719bde6913ec00a646bbef710e45eadffd8c32a4cb6e912881033</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Black People</topic><topic>Blood Pressure</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Hydrochlorothiazide</topic><topic>Hypotension</topic><topic>Melanoma</topic><topic>Skin cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dominguez-Rodriguez, Alberto</creatorcontrib><creatorcontrib>Baez-Ferrer, Nestor</creatorcontrib><creatorcontrib>Abreu-Gonzalez, Pedro</creatorcontrib><creatorcontrib>KagboKue, Suaka</creatorcontrib><creatorcontrib>Chineke, Iloabueke</creatorcontrib><creatorcontrib>Bakinde, Nicholas</creatorcontrib><creatorcontrib>Schwartz, Jeremy I</creatorcontrib><creatorcontrib>Ssinabulya, Isaac</creatorcontrib><creatorcontrib>Quashie, Nekehia T</creatorcontrib><creatorcontrib>Howitt, Christina</creatorcontrib><creatorcontrib>Hambleton, Ian R</creatorcontrib><creatorcontrib>Ojji, Dike B</creatorcontrib><creatorcontrib>Poulter, Neil</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dominguez-Rodriguez, Alberto</au><au>Baez-Ferrer, Nestor</au><au>Abreu-Gonzalez, Pedro</au><au>KagboKue, Suaka</au><au>Chineke, Iloabueke</au><au>Bakinde, Nicholas</au><au>Schwartz, Jeremy I</au><au>Ssinabulya, Isaac</au><au>Quashie, Nekehia T</au><au>Howitt, Christina</au><au>Hambleton, Ian R</au><au>Ojji, Dike B</au><au>Poulter, Neil</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2019-10-03</date><risdate>2019</risdate><volume>381</volume><issue>14</issue><spage>1389</spage><epage>1392</epage><pages>1389-1392</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>To the Editor:
Ojji et al. (June 20 issue)
1
report that amlodipine plus hydrochlorothiazide effectively lowered blood pressure at 6 months in black patients in sub-Saharan Africa. Many primary care providers are unaware of the association between hydrochlorothiazide use and skin cancer.
2
The Medicines and Healthcare Products Regulatory Agency has reported a dose-dependent risk of lip and skin cancers among patients taking hydrochlorothiazide.
2
Regarding melanoma,
3
413 cases were identified among high users of hydrochlorothiazide (patients who had taken a cumulative dose of ≥50,000 mg of hydrochlorothiazide), yielding an adjusted odds ratio of 1.22 (95% confidence interval [CI], 1.09 to 1.36), . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>31577885</pmid><doi>10.1056/NEJMc1909844</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2019-10, Vol.381 (14), p.1389-1392 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2300597847 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Black People Blood Pressure Health risk assessment Humans Hydrochlorothiazide Hypotension Melanoma Skin cancer |
| title | Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A09%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20Dual%20Therapies%20for%20Lowering%20Blood%20Pressure%20in%20Black%20Africans&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Dominguez-Rodriguez,%20Alberto&rft.date=2019-10-03&rft.volume=381&rft.issue=14&rft.spage=1389&rft.epage=1392&rft.pages=1389-1392&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1909844&rft_dat=%3Cproquest_cross%3E2300595809%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2300236520&rft_id=info:pmid/31577885&rfr_iscdi=true |